Er is verder onderzoek nodig om de bevindingen van de cohort study te valideren (bevestigen).
Journal of Clinical Microbiology; Bron https://jcm.asm.org/
Publicatie 21 april 2021
Study - 'Diagnostic performance of the novel BioPlex Lyme serological assays in European patients with Lyme disease' by M.E. (Ewoud) Baarsma, Jeanine Ursinus, Hans L. Zaaijer, Herman Kuiper, Joppe W. Hovius; Bron https://jcm.asm.org/content/early/2021/ ... M.03205-20
Serodiagnosis of Lyme borreliosis (LB) comes with several drawbacks, among which limited sensitivity in early disease. This study assesses the sensitivity and specificity of the novel BioPlex 2200 Lyme IgG & Lyme IgM assays. It also assesses potential improvements to the assays through ROC-analysis.
The BioPlex assays were performed on sera of 158 Dutch patients with physician-confirmed LB (both early localized and disseminated), 800 healthy blood donors from the Netherlands and 90 cross-reactive controls. The BioPlex assays were compared with two commercial enzyme immunoassays (Euroimmun/C6-ELISA) and one immunoblot (recomLine).
The BioPlex 2200 Lyme IgG & Lyme IgM assays are promising tools for the serodiagnosis of early LB, with the potential to be used as a standalone test. Further research is necessary to validate the findings of this discovery cohort.